11 Analysts Assess Taysha Gene Therapies: What You Need To Know

Throughout the last three months, 11 analysts have evaluated Taysha Gene Therapies TSHA, offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.82, a high estimate of $9.00, and a low estimate of $5.00. Marking an increase of 36.4%, the current average surpasses the previous average price target of $5.00.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Taysha Gene Therapies among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Taysha Gene Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Taysha Gene Therapies compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Taysha Gene Therapies's stock. This examination reveals shifts in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Taysha Gene Therapies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Taysha Gene Therapies analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

A Deep Dive into Taysha Gene Therapies's Financials

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Positive Revenue Trend: Examining Taysha Gene Therapies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 44.04% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Taysha Gene Therapies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1324.67%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Taysha Gene Therapies's ROE stands out, surpassing industry averages. With an impressive ROE of 369.76%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Taysha Gene Therapies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 25.91%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.82, caution is advised due to increased financial risk.

Understanding the Relevance of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.